Identified in 15–20% of all breast cancers, HER2 protein overexpression and/or gene amplification has been shown to characterize an aggressive disease subgroup with high invasive and metastatic potential, resistance to hormonal and chemotherapy regimens, and poor outcome [5,6]. Here, ERBB2 is linked to breast carcinoma.